Dongwu Securities gives Xinli Tai a "Buy" rating, highlighting its position as an innovative leader in the chronic disease field, with significant potential for the heart failure heavyweight JK07.

Jingjing AI Express: On April 1, Soochow Securities released a research report saying it gives a “Buy” rating to Xintai (002294.SZ, latest price: 66.05 yuan). The main reasons include: 1) An innovation-driven transformation of an established chronic-disease leader; major product categories are expected to contribute revenues in the billions; 2) A brand-new BIC molecule mechanism; JK07 is expected to disrupt the global heart failure market landscape; 3) Leading with the first domestically developed ARNI drug, with the product matrix for hypertension comprehensively upgraded; 4) Metabolism, nephrology, and orthopedics advancing in parallel—sales growth is smooth, and the pipeline is well-stocked. Risk reminders: the risk of product R&D failure; the risk that drug sales fall short of expectations; uncertainty regarding how the centralized procurement (volume-based) policy will affect product pricing.

Jingjing Toutiao (nbdtoutiao) — These “dormant” accounts will be cleaned up! Several banks have recently announced it

(Reporter: Zeng Jianhui)

Disclaimer: The content and data in this article are for reference only and do not constitute investment advice. Please verify before using. If you act based on this, you assume the risk.

Daily Economic News